Tesamorelin (10mg): The Ultimate Peptide for Targeting Visceral Belly Fat

Tesamorelin – Targeted Visceral Fat Reduction & GH Optimization Peptide

Harness the power of endogenous growth hormone stimulation with Tesamorelin (tesamorelin acetate), a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH). FDA-approved under brand names like Egrifta SV and Egrifta WR specifically for reducing excess abdominal (visceral) fat in HIV-infected adults with lipodystrophy, Tesamorelin stands out for its selective action on deep belly fat while supporting metabolic health and body composition.

Key Features & Benefits:

• Visceral Fat Reduction — Clinically proven to significantly decrease visceral adipose tissue (VAT) around organs, helping improve waist circumference and metabolic profiles without substantial total body weight loss.
• Growth Hormone Stimulation — Binds to pituitary GHRH receptors to promote natural, pulsatile GH release, elevating IGF-1 levels for enhanced fat metabolism, protein synthesis, and anabolic support.
• Metabolic & Lipid Support — May improve lipid profiles, insulin sensitivity markers (in context), and overall energy utilization in research settings.
• Lean Mass Preservation — Helps maintain or subtly enhance muscle quality and density during fat-loss phases, making it appealing for body recomposition.
• Convenient Daily Dosing — Administered as a once-daily subcutaneous injection, typically in the abdomen, for consistent GH signaling.

Why Choose Tesamorelin? Unlike direct GH injections or broader GHRH analogs, Tesamorelin’s modified structure (with a hexenoyl moiety for stability) provides targeted visceral fat mobilization with a more physiologic GH pulse pattern. In approved use, patients often experience meaningful reductions in abdominal fat accumulation associated with HIV therapy. In wellness and performance communities, it’s valued for supporting a leaner midsection, better recovery, and metabolic optimization — especially when paired with diet, exercise, and lifestyle factors.

Administration & Convenience: Supplied as lyophilized powder in single-dose vials  reconstituted with sterile water for injection. Standard approved dosing is approximately 1.4–2 mg (or equivalent adjusted dose) subcutaneously once daily, often in the morning or evening per protocol. Research/off-label cycles typically last 3–6 months or longer.